Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harmony Biosciences Holdings ( (HRMY) ) has shared an announcement.
On March 24, 2025, Harmony Biosciences announced the departure of Jeffrey Dierks as Chief Commercial Officer, effective March 31, 2025, and the appointment of Adam Zaeske as his successor. Zaeske, with over 25 years of experience in the pharmaceutical industry, is expected to lead the company’s commercial strategy and expansion efforts, building on the success of WAKIX and advancing Harmony’s late-stage pipeline assets.
More about Harmony Biosciences Holdings
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for rare neurological diseases. Its flagship product, WAKIX (pitolisant), is approved for treating excessive daytime sleepiness and cataplexy in narcolepsy patients.
YTD Price Performance: 1.29%
Average Trading Volume: 639,790
Technical Sentiment Signal: Buy
Current Market Cap: $2.02B
For detailed information about HRMY stock, go to TipRanks’ Stock Analysis page.